US cardiovascular drug developer's Q2 net loss widened yr/yr on higher R&D and admin expenses
Company completed $2.65 bln sale of muscular dystrophy business to Servier in July 2026
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
$57.33 mln
Q2 Loss Per Basic Share
$0.53
Q2 Operating Expenses
$61.94 mln
Q2 Operating Income
-$61.94 mln
Result Drivers
Organizational expansion - Co said higher G&A expenses reflected increased personnel costs, stock-based compensation, and professional fees to support clinical development
Strategic focus shift - Sale of muscular dystrophy business to Servier strengthened balance sheet and sharpened focus on cardiovascular pipeline
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
EWTX•
